<?xml version='1.0' encoding='utf-8'?>
<document id="23992134"><sentence text="Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data." /><sentence text="Fourteen drugs targeting protein kinases have been approved by the United States Food and Drug Administration (FDA) between the years 2000 and 2011" /><sentence text=" While the mechanisms of action and clinical data have been reported, the preclinical absorption, distribution, metabolism and elimination (ADME) data on these compounds are not readily available" /><sentence text="" /><sentence text="This review summarizes the structural, physicochemical and preclinical ADME properties of the 14 kinase inhibitors" /><sentence text=" For this purpose, the authors identified common preclinical ADME features of the majority of these inhibitors" /><sentence text="" /><sentence text="The authors believe engendering a combination of the following attributes will greatly improve one's chance of discovering kinase inhibitors with a successful development path: i) Lipinski Rule of Five and Veber's rules, ii) most basic pKa values â‰¤ 9, iii) low to moderate clearance values for each species and iv) moderate to high Caco-2 permeability" /><sentence text=" Furthermore, they recommend primarily focusing on in vitro hepatic stability and rodent in vivo disposition properties at early screening stage and using Caco-2 permeability/efflux ratio to salvage compounds with rapid rodent plasma clearance" /><sentence text=" In vitro drug-drug interaction data should be evaluated in the context of the dosing route, dosing regimen, elimination pathways, enzyme phenotyping profile, efficacious exposure and the target disease" /><sentence text="" /></document>